海圣医疗本次发行募集资金总额为142,757,651.52元，募集资金净额为113,438,208.84元，拟用于麻 醉监护急救系列医疗器械升级扩产及自动化项目、研发检测中心项目、营销服务基地建设项目。 公司是面向全球的麻醉、监护类医疗器械综合产品提供商，主营业务为麻醉、监护类医疗器械产品 的研发、生产和销售，产品已广泛应用于麻醉科、ICU病房、急诊科等科室的终端临床需求。 (责任编辑：蔡情) 中国经济网北京2月12日讯 今日，海圣医疗（920166）在北交所上市。 本次发行前，黄海生直接持有公司47.11%的股份，为公司控股股东，黄海生及吴晓晔系夫妻，黄 海生直接持有公司47.11%的股份，吴晓晔持有励新投资20.60%财产份额，通过励新投资间接控制公司 7.81%的股份。黄海生及吴晓晔夫妇两人合计控制公司54.92%的股份。黄海生及吴晓晔系公司实际控制 人。本次发行前后，公司控股股东、实际控制人未发生变化。 北交所：海圣医疗（920166） ...

（来源：中国医药报） 转自：中国医药报 □ 王嘉薇 方深科 赵阳 自国家药监局部署实施"春雨行动"以来，浙江省药监局通过深化前置服务、强化研审联动、拓展部门协 作，努力打通医疗器械从"实验室"到"生产线"的转化路径，助推"浙造器械"在政策"春雨"滋润下焕发蓬 勃生机，结出丰硕成果。 强化顶层设计 构建协同推进"一盘棋" 浙江省药监局坚持制度先行、联动发力，为"春雨行动"落地提供坚实的组织保障和机制支撑。"春雨行 动"启动后，浙江省药监局党组高度重视，第一时间召开专题部署会，组建"春雨行动"工作专班，制定 细化实施方案，建立定期会商、信息通报、督导落实等工作机制，确保责任到人、任务到岗、措施到 位，形成高效运转的内部推进体系。与此同时，积极争取并成功为浙江省医疗器械审评中心新增事业编 制19名，显著增强了省级审评核心力量。 临床成果转化涉及多环节、多部门，浙江省药监局主动加强部门协同，凝聚创新合力。浙江省药监局与 省卫生健康委迅速达成共识，联合推进"春雨行动"。浙江省医疗器械审评中心与省医学教育科技发展中 心（省卫生健康委直属单位）联合发文，面向全省各级医疗机构广泛征集临床研究成果转化项目，扩大 政策知晓度和覆 ...

播洒政策"及时雨" "以前，医疗机构、科研院所的很多科研项目止步于获得发明专利、刊发学术文章，转化为医疗器械的 意识不足。近年来，随着各相关机构推进纵向课题研究，鼓励研究成果转化，'不会转'的问题变得更加 突出。"四川省药监局医疗器械注册管理处工作人员蔡云龙介绍，临床医生和技术专家在医疗器械开发 上面临知识体系差异、研发协作、法规理解等多方面困难。 这并非一时一地的挑战。临床需求是医疗器械创新的源头活水，如何让一线的创新灵感转化出医疗器 械？借助"春雨行动"，各试点省份着力破题解难。 "春雨行动"启动以来，试点省份药品监管部门主动向前一步，深入医疗机构，传递政策导向，深入探讨 医工转化面临的现实瓶颈，研究解决策略，并向临床医生抛出"橄榄枝"。 2025年6月，在北京举办的医疗器械临床研究成果转化推进会覆盖了132家三级医院、10家科研院所及50 家领军企业。会议不仅介绍相关政策，还由医疗机构代表与企业代表分享医工协同创新的实践路径，展 示从临床痛点挖掘、跨学科团队组建到技术难题攻克的全流程转化经验。 （来源：中国医药报） 转自：中国医药报 医疗器械临床研究成果转化"春雨行动"持续推进，多地药品监管部门在新一年 ...

要让医疗器械创新发展真正驶入快车道，各级药品监管部门须以"春雨行动"为契机，正确把握安全监 管、产业发展与为民服务的关系，做到"保安全"与"促发展"有机统一。 （来源：中国医药报） 转自：中国医药报 □ 本报特约评论员 创新是引领发展的第一动力，是医疗器械产业高质量发展的生命力。2025年4月，国家药监局启动"春雨 行动"，聚焦打通临床创意到产品上市的全链条堵点，推动医疗器械源头创新高效转化。短短数月内， 11个试点地区积极探索，涌现出一批新做法和新成效，推动我国医疗器械创新生态体系建设迈入新阶 段，也彰显了药品监管部门统筹发展与安全、服务新质生产力的战略远见。 好雨知时节，当春乃发生。正如春雨催生春意，催发生机和活力。"春雨行动"并非简单征集临床研究成 果项目，而是构建覆盖"需求挖掘—平台对接—审评提速—政策协同"的全链条服务体系，着力破解长期 存在的"临床需求找不到企业承接、企业研发找不到临床痛点"难题。其核心是以临床价值为导向，"从 患者中来、到患者中去"，真正践行"监管为民"理念，为医疗器械创新发展提供不竭动力。 各地因地制宜的探索，印证了"春雨行动"的可操作性：广东省药监局以"四个一"落实"春雨行动 ...

Core Insights - The "Spring Rain Action" initiated by the National Medical Products Administration in April 2025 aims to promote clinical innovation in Jilin Province, focusing on transforming clinical ideas into viable products [2][5] - As of January 2026, Jilin Province has identified 29 high-quality clinical transformation projects, with 12 third-class medical device projects submitted to the National Medical Products Administration for review [1][5] Group 1: Policy and Implementation - Jilin Province's Medical Products Administration has developed a comprehensive process for project collection, expert review, and follow-up support, emphasizing clinical value-driven innovation [2][4] - Training teams have been organized to educate clinical workers on policy interpretation and project submission processes, ensuring broad participation and high-quality project sources [2][3] Group 2: Project Evaluation and Selection - A multi-dimensional evaluation mechanism has been established to select the most promising projects from the 47 submitted, with 80% focusing on urgent clinical needs [4][5] - On September 30, 2025, 29 projects were selected for review, with a focus on medical devices and diagnostic reagents that align with the province's healthcare goals [4][5] Group 3: Project Support and Development - The Jilin Province Medical Products Administration has implemented a full-chain tracking and nurturing mechanism to support the transformation of selected projects [6][7] - As of the end of 2025, three of the twelve third-class medical device projects have entered clinical trial stages, and five have completed product design, with others progressing as planned [7]

Core Viewpoint - The article emphasizes the importance of facilitating the transformation of clinical innovations into medical products that benefit patients, highlighting Beijing's "Spring Rain Action" as a key initiative to enhance innovation in the medical and health industry [1] Group 1: Policy and Support Mechanisms - Beijing has established a "policy coordination + full-chain service" support system to optimize the innovation environment, combining top-level design with systematic policy support [2] - Since 2018, Beijing has implemented three rounds of collaborative innovation action plans in the medical and health sector, introducing measures to support high-quality development in innovative pharmaceuticals [2] - The "Spring Rain Action," led by the National Medical Products Administration, was launched in April 2025, creating a collaborative mechanism among various departments to promote the transformation of innovative medical device results [2][3] Group 2: Innovation Ecosystem Development - Beijing has built an innovation ecosystem characterized by city-district collaboration and medical-enterprise cooperation, enhancing the internal motivation for deep collaboration between medical institutions and enterprises [4] - As of October 2025, the Beijing Medical Products Administration has collected information on 220 medical device projects, with 87 projects selected for focused cultivation, marking a new phase in the "Spring Rain Action" [4] - The collaboration mechanism ensures that innovative products are closely aligned with clinical needs from the design stage, facilitating safe and effective applications in clinical settings [6] Group 3: Product Development and Market Entry - The Beijing Medical Products Administration has implemented a "graded cultivation + review linkage" mechanism to support product market entry, providing tailored guidance for different categories of medical devices [7] - As of December 2025, one third-class medical device has entered the special review process, with four third-class devices prioritized for approval, demonstrating the effectiveness of the "Spring Rain Action" [7] - The initiative aims to create a comprehensive innovation ecosystem that integrates policy innovation, clinical resources, and industry collaboration, ensuring sustainable growth in the medical health sector [8]

（来源：中国医药报） 转自：中国医药报 □ 宋红霞 魏畅 赵元煜 多方协同筑牢保障 为确保平台发挥实效，河北省药监局积极构建多维度协同保障机制，全方位推动平台高效运行与服务优 化。 医疗器械临床成果转化，曾长期面临"医生找不到企业、企业找不准项目"的对接之困。如今，在河北， 这一痛点正被一个数字化平台破解。河北省药监局打造的"河北省医疗器械创新服务平台"（以下简称平 台），正以"一站式"线上服务，打通从临床创意到产业成果落地的关键路径。 目前，平台已开展试运行，并成功推动一批临床项目与企业实现合作，显著提升了转化效率。截至2026 年1月，平台已收集临床创新创意126个，并从中筛选出52个临床价值明确、转化前景良好的优质项目纳 入储备。 数据归集夯实根基 平台以"项目库、企业库、专家库、法规库"为核心数据支撑，打破信息壁垒，推动创新要素集聚，实 现"一网归集、动态更新"。 目前，项目库已收录临床项目50余项，涵盖心血管、骨科、影像等重点领域。每个项目均建立了详细的 信息档案，不仅包含项目名称、研发团队、技术原理、创新点等基础内容，还精准标注了转化需求、合 作模式、市场预估等关键信息。通过标准化的数据录入与分类 ...

南方医科大学珠江医院研发的SMART互动式AI认知早筛系统，有望以无创、低成本方式实现阿尔茨海 默病社区早期筛查；中山大学附属第一医院苏培强教授团队首创的动态脊柱侧弯矫正系统，有望在保障 矫形效果的同时，保留脊柱生理活动功能……这些"小而美、专而精"的项目，正是"春雨行动"激活临床 创新动能的生动体现。 （来源：中国医药报） 转自：中国医药报 2025年4月，国家药监局启动"春雨行动"。广东省药监局深入贯彻落实相关部署要求，聚焦破解临床研 究成果转化中"不愿转、不敢转、不会转"的现实难题，系统推动制度创新、机制重构与服务升级，全面 激活广东医疗器械源头创新活力。截至今年1月底，已收集400余个项目，并筛选出55个临床价值较高的 第三类医疗器械产品上报国家药监局医疗器械技术审评中心（以下简称国家药监局器审中心）。 建立"金标准"选出"金点子" "春雨行动"启动后，广东省药监局制定关于开展"春雨行动"——推进医疗器械临床研究成果转化工作的 实施方案，同步起草《春雨行动项目临床价值筛选评价参考标准（试行）》，构建临床研究成果项目收 集筛选机制，推动搭建广东临床转化平台，多维发力确保行动高效推进。 标准是筛选项目的重 ...

Group 1 - The overall market size of surgical robots in China is expected to grow from 7.2 billion RMB in 2024 to 76.7 billion RMB by 2032, with a CAGR of approximately 34% [1] - The market for laparoscopic surgical robots is projected to have a CAGR of about 29% from 2024 to 2032, driven by the release of pricing directories and increased penetration rates [1] - The orthopedic surgical robot market is anticipated to grow at a CAGR of around 41% during the same period, benefiting from the implementation of pricing directories and accelerated hospital admissions [1] Group 2 - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will lead to a continuous increase in consumables, generating stable revenue and cash flow [2] - The global market for leading surgical robot companies has surpassed 1 trillion RMB, with significant growth potential in penetration rates and market size [2] - AI is expected to empower surgical robots to achieve autonomous operations, further enhancing industry penetration rates and improving valuations of related companies [2] Group 3 - Related Hong Kong stocks in the surgical robot sector include Precision Medicine-B (02675), MicroPort Scientific Corporation-B (02252), and Kangji Medical (09997) [3]

*免责声明：文章内容仅供参考，不构成投资建议 | | | 海圣医疗(北交所,920 | | | --- | --- | --- | --- | | 发行价格 | 12.64元 | | | | 智签率 | 0.02% | | 询价 | | 总市值 | | | | | 发行市盈率 | 13.99 | | 行业 | | 业务及亮点 | 公司主营业务为麻醉、监护类医疗器械产品的 1、 | | | | | ICU 病房、急诊科等科室的终端临床需求。 | | | | | 2、公司已搭建起麻醉类、监护类、手术及护理类 | | | | | 品矩阵,掌握 14 项核心技术,为产品矩阵构筑了 | | | | | 3、公司主要产品广泛应用于全国上千家三级医院 | | | | | MEDTRONIC/COVIDIEN（美敦力 / 柯惠医疗公司 | | | *风险提示：股市有风险，入市需谨慎 ...